Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Metabolic Dysfunction-associated Steatohepatitis: early-phase trial registry

4 of 6 indexed Metabolic Dysfunction-associated Steatohepatitis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Metabolic Dysfunction-associated Steatohepatitis: 6 US clinical trials tracked, 4 recruiting.

Metabolic Dysfunction-associated Steatohepatitis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Boston Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition metabolic-dysfunction-associated-steatohepatitis

OPEN 4 | RECR 67% | LATE 1 | EARLY 4 | RANK #2866 | SPON 1

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Metabolic Dysfunction-as (th…67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Metabolic Dysfunction-associated Steatohepatitis

Metabolic Dysfunction-associated Steatohepatitis lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metabolic Dysfunction-associated Steatohepatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metabolic Dysfunction-associated Steatohepatitis is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metabolic Dysfunction-associated Steatohepatitis research.

    Boston Pharmaceuticals accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Metabolic Dysfunction-associated Steatohepatitis enrolment sits around 132 participants.

    Median target enrolment is 132 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.

  4. Metabolic Dysfunction-associated Steatohepatitis research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 31

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Metabolic Dysfunction-associated Steatohepatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
ALG-055009 Drug
1 trials
Efinopegdutide Combination
1 trials
Placebo matching survodutide Combination
1 trials
Survodutide Combination
1 trials
Efimosfermin Drug
1 trials
Lifestyle modification Behavioral
1 trials
ESG + lifestyle modification Device
1 trials

US sites by state

Facility locations filed on Metabolic Dysfunction-associated Steatohepatitis trials. A trial with sites in several states counts in each.

California 5 trials
Arizona 5 trials
Georgia 4 trials
Florida 4 trials
Maryland 2 trials
Louisiana 2 trials
West Virginia 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metabolic Dysfunction-associated Steatohepatitis page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Metabolic Dysfunction-associated Steatohepatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Boston Pharmaceuticals sponsors the most Metabolic Dysfunction-associated Steatohepatitis trials on record, review their full trial history before evaluating a specific study. See Boston Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolic Dysfunction-associated Steatohepatitis condition card totals 6 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.